IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
about
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trialUpdate on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphomaHuman leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma?Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.Current management of follicular lymphomas.Management of indolent lymphoma: where are we now and where are we going.GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.Siglecs as targets for therapy in immune-cell-mediated disease.Anti-CD20 monoclonal antibodies: historical and future perspectives.Autologous transplant of follicular lymphoma in the era of rituximab.The role of monoclonal antibodies in the treatment of lymphomas.The optimal management of follicular lymphoma: an evolving field.Treatment approaches to asymptomatic follicular lymphoma.Acute jugular vein thrombosis during rituximab administration: Review of the literature.Chemotherapy-free treatment in patients with follicular lymphoma.Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients.Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
P2860
Q33626106-5F79CE8F-6D18-4949-9174-7F6173A653F6Q33830194-1324C5DE-D750-4191-9D11-B93C7337DF23Q33915986-D167FB5B-9C27-4544-AF79-6DC8E0BCABBCQ34451956-30142579-3463-486F-BC9A-14AA3109862FQ34700655-3BBBCDAD-2597-4C9B-A4A2-C669A4CAD2B4Q35022123-FD74F150-613C-4EC5-8AA1-536F525A2B73Q36411719-2325398E-2F46-4BF0-AB5E-24F4894E2117Q36639053-D844201D-4238-48EA-86BC-2E64181E59B0Q36784860-AB4973B6-CE17-4863-986B-0E710D2A15FFQ37271831-DA52DBBE-6B84-4479-B703-3DCF0B68C2D8Q37440061-03815D2D-8DB1-427A-A0EB-039402E37BF0Q37601775-34559039-F78E-47B8-817A-1CB021A0D9E2Q37742624-E934AFF3-0BCB-40B1-99C3-2C859DDBABC9Q38069595-A6CF28E1-8DC3-4402-9900-CFFAB5EF8BF9Q38124009-5D32A15C-A1EF-4746-8839-81DE6C12D2BFQ38161963-F178760E-3B4D-494E-847F-D4573D8E0D47Q38234141-E0F696BD-638F-4C0B-8C3E-7E9931C734B0Q38317235-228DE27F-0E7F-4522-A9BE-AEFE3784DC9BQ44003995-6DBDB64E-4C4A-451D-9C81-1ADFAA56D0C1Q45055440-C8940574-E0F8-4936-93F6-01718B12189AQ46675870-8ACE49A1-4C84-4976-BBAB-1CF22ADB7F45Q47830676-757C5099-21E3-48AB-A927-0627D4CB1FE3Q52880098-C5A1B9D5-BC42-4F0C-841E-5996E818590A
P2860
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@en
type
label
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@en
prefLabel
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@en
P2093
P356
P1433
P1476
IDEC-C2B8 (Rituximab) anti-CD2 ...... ow-Grade Lymphoma Study Group.
@en
P2093
Atzpodien J
Aulitzky E
Feuring-Buske M
Gramatzki M
Hiddemann W
P304
P356
10.1007/S002770000163
P577
2000-09-01T00:00:00Z